Treatment Modification to Reduce Symptom Burden in Hemodialysis
- Conditions
- End Stage Renal Disease
- Registration Number
- NCT01775800
- Lead Sponsor
- The Rogosin Institute
- Brief Summary
Many patients on hemodialysis experience high rates of symptom burden, such as pain, depression, anxiety and difficulty breathing. This study seeks to reduce these symptoms by modifying the usual guidelines used to manage patients on hemodialysis. For example, rather than trying to keep serum phosphorus below 5.5, patients enrolled in this study may have treatment goals of less than 6.5, in order to reduce the number of pills they need to take and potentially reduce harmful side effects. Blood pressure and serum parathyroid hormone goals will also be modified, to see if these modifications help hemodialysis patients feel better.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 16
- hemodialysis patient
- transplant ineligible
- dementia
- unable to answer questionnaires for any reason
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Number of Participants Recruited, Consented, Randomized and Completed Each participant was assessed for 6 weeks; total recruitment period was 15 months
- Secondary Outcome Measures
Name Time Method Symptom Burden Baseline and 6 weeks Number of symptoms in past week as measured by the Dialysis Symptom Index
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
The Rogosin Institute
🇺🇸New York, New York, United States
The Rogosin Institute🇺🇸New York, New York, United States